The WuXi AppTec-backed infectious disease therapeutics developer has closed a series C round featuring various investment managers and Singapore's sovereign wealth fund.

New and existing investors provided crossover financing for the synthetic biology technology developer, which already counts Merck & Co, AGC Asahi Glass and JSR Life Sciences as investors.

Newly minted strategic partner Hitachi Construction Machinery was among the investors in a $30.4m round for the lidar system developer.

Asher Bio has launched with $55m in series A financing to commercialise research partially conducted at WashU and Leiden.

The supply chain software provider, which counts Telkom Indonesia, Deutsche Telekom, Jebsen & Jessen and Telkomsel as investors, has now raised over $42m in total.

The risk management software developer secured $17.9m in a GV-led round that included LocalGlobe and Entrepreneur First.

M12 co-led a $22m series A round for the drug discovery technology developer with Playground Global, and both investors have taken board seats.

Cedars-Sinai contributed to a round boosting the virtual reality therapeutics developer's overall funding to $35m.

The iFlytek-backed post-discharge care management platform received $23m in a round led by Sequoia Capital China.